Theriva Biologics, Inc.TOVXNYSE
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank95
5Y CAGR+20.1%
Year-over-Year Change
Year-over-year net income growth rate
5Y CAGR
+20.1%/yr
Long-term compound
Percentile
P95
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 66.60% |
| Q2 2025 | -201.99% |
| Q1 2025 | 2.77% |
| Q4 2024 | 42.44% |
| Q3 2024 | 7.09% |
| Q2 2024 | -61.01% |
| Q1 2024 | 5.83% |
| Q4 2023 | -66.06% |
| Q3 2023 | 35.03% |
| Q2 2023 | -13.53% |
| Q1 2023 | 30.52% |
| Q4 2022 | -43.54% |
| Q3 2022 | -0.29% |
| Q2 2022 | -4.77% |
| Q1 2022 | 18.81% |
| Q4 2021 | -60.80% |
| Q3 2021 | -2.44% |
| Q2 2021 | -25.99% |
| Q1 2021 | -20.25% |
| Q4 2020 | -0.29% |
| Q3 2020 | 26.65% |
| Q2 2020 | 3.27% |
| Q1 2020 | 5.61% |
| Q4 2019 | 38.67% |
| Q3 2019 | -45.00% |
| Q2 2019 | -0.54% |
| Q1 2019 | -10.68% |
| Q4 2018 | 13.78% |
| Q3 2018 | 12.32% |
| Q2 2018 | -81.22% |
| Q1 2018 | -181.26% |
| Q4 2017 | 126.09% |
| Q3 2017 | -156.69% |
| Q2 2017 | -49.51% |
| Q1 2017 | -19.83% |
| Q4 2016 | 71.57% |
| Q3 2016 | -47.01% |
| Q2 2016 | 47.61% |
| Q1 2016 | 1.25% |
| Q4 2015 | -62.12% |